🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Safety and Performance of ENDOMATIC SEPIOLA Left Atrial Appendage (LAA) Closure Device

RecruitingNAAges 18 Years - anyAllEndomatic Ltd.
NCT06099106 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The study is designed to evaluate the safety and performance of the ENDOMATIC SEPIOLA Left Atrial Appendage (LAA) Closure Device in Patients with non-valvular Atrial Fibrillation, who are at increased risk for stroke, and that cannot take, or have a reason to seek an alternative, to long-term anticoagulation therapy. Potential patients who are candidates for LAA closure will be screened to confirm that all inclusion/exclusion criteria are met, with final eligibility confirmation on day of procedure. All enrolled subjects who went through the procedure will be followed during the procedure to hospital discharge. Additional follow up time points are scheduled at 45 days, 6 months and 12 months post procedure.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * calculated CHA2DS2-VASc score of 2 or greater. * The subject is non-eligible or have an appropriate rationale to seek a non-pharmacologic alternative to chronic oral anticoagulants. * documented non-valvular atrial fibrillation * Subject suitable for vascular/cardiac intervention procedure * suitable LAA anatomical measurements for study device Exclusion Criteria: * Subject who requires anticoagulation for a condition other than AF. * NYHA classification IV. * Complex congenital heart disease. * Presence of circumflex coronary artery stent. * The subject has a prosthetic valve in any position. * atrial septal defect closure or has an ASD/PFO device. * presence of intracardiac thrombus. * Any cardiac surgery in the past * LVEF \< 35%. * intracardiac thrombus * moderate or severe mitral valve stenosis
💊

What it tests

  • SEPIOLA System
📍

Where

5 sites
Israeli-Georgian Medical Research Clinic Helsicore
Tbilisi, Georgia
Tbilisi Heart and Vascular Clinic
Tbilisi, Georgia
Vilnius university hospital Santaros Klinikos
Vilnius, Lithuania
Uniwersytecki Szpital Kliniczny w Poznaniu
Poznan, Poland
Ezgu Niyat
Tashkent, Uzbekistan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy